Quantitation of ARGS aggrecan fragments in synovial fluid, serum and urine from osteoarthritis patients

Osteoarthritis and Cartilage

Volumn 22, Issue 5, 2014, Pages 690-697

  Germaschewski, F M ^a   Matheny, C J ^b   Larkin, J ^b   Liu, F ^b   Thomas, L R ^a   Saunders, J S ^b   Sully, K ^a   Whittall, C ^c   Boyle, Y ^a   Peters, G ^a   Graham, N M ^c  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

^c ROBERT JONES AND AGNES HUNT ORTHOPAEDIC HOSPITAL   (United Kingdom)

Author keywords

Aggrecan; ARGS; Biomarker; Immunoassay; Neoepitope; Osteoarthritis

Indexed keywords

AGGRECAN; AGGRECANASE 2; ARGS NEOEPITOPE; CREATININE; DISINTEGRIN; EPITOPE; THROMBOSPONDIN; UNCLASSIFIED DRUG; ADAM PROTEIN; ADAMTS5 PROTEIN, HUMAN; BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOASSAY; KNEE OSTEOARTHRITIS; LIMIT OF QUANTITATION; MALE; PRIORITY JOURNAL; PROTEIN MOTIF; SCORING SYSTEM; SERUM; SYNOVIAL FLUID; TOTAL KNEE REPLACEMENT; URINALYSIS; CASE CONTROL STUDY; CHEMISTRY; CIRCADIAN RHYTHM; KNEE ARTHROPLASTY; LUMINESCENCE; METABOLISM; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PHYSIOLOGY; PROCEDURES;

ADAM PROTEINS; AGED; AGGRECANS; ARTHROPLASTY, REPLACEMENT, KNEE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CIRCADIAN RHYTHM; EPITOPES; FEMALE; HUMANS; LUMINESCENT MEASUREMENTS; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PEPTIDE FRAGMENTS; SYNOVIAL FLUID;

EID: 84899966048     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2014.02.930     Document Type: Article

References (22)

1. Glasson S.S., Askew R., Sheppard B., Carito B., Blanchet T., Ma H.L. Deletion of active ADAMTS-5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 2005, 434:644-648.
2. Stanton H., Rogerson F.M., East G.J., Golub S.B., Lawlor K.E., Meeker C.T. ADAMTS-5 is the major aggrecanase in mouse cartilage invivo and invitro. Nature 2005, 434:648-652.
3. Little C.B., Meeker C.T., Golub S.B., Lawlor K.E., Farmer P.J., Smith S.M. Blocking aggrecanase cleave in the aggrecan interglobular domain abrogates cartilage erosion and promotes cartilage repair. JClin Invest 2007, 117:1627-1636.
4. Burden MN, Hamblin PA, Larkin JD, White JR. Polypeptides and methods of treatment. Patent WO2011/002968 A2; 2011.
5. Sandy J.D., Flannery C.R., Neame P.J., Lohmander L.S. The structure of aggrecan fragments in human synovial fluid. Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Clu 373-Ala 374 bond of the intergobular domain. JClin Invest 1992, 89:1512-1516.
6. Struglics A., Larsson S., Pratta M.A., Kumar S., Lark M.W., Lohmander L.S. Human osteoarthritis synovial fluid and joint cartilage contain both aggrecanase- and matrix metalloproteinase-generated aggrecan fragments. Osteoarthritis Cartilage 2006, 14(2):101-113.
7. Pratta M.A., Su J.L., Leesnitzer M.A., Struglics A., Larsson S., Lohmander L.S., et al. Development and characterization of a highly specific and sensitive sandwich ELISA for detection of aggrecanase-generated aggrecan fragments. Osteoarthritis Cartilage 2006, 14:702-713.
8. Will H., Dettloff M., Bendzko P., Sveshnikov P. Aquantitative assay for aggrecanase activity. JBiomol Tech 2005, 16:459.
9. Swearingen C.A., Carpenter J.W., Siegel R., Brittain I.J., Dotzlaf J., Durham T.B., et al. Development of a novel clinical biomarker assay to detect and quantify aggrecanase-generated aggrecan fragments in human synovial fluid, serum and urine. Osteoarthritis Cartilage 2010, 18:1150-1158.
10. Larsson S., Lohmander L.S., Struglics A. Synovial fluid level of aggrecan ARGS fragments is a more sensitive marker of joint disease than glycosaminoglycan or aggrecan levels: a cross-sectional study. Arthritis-Research Ther 2009, 11. R92 1-11.
11. Larsson S., Englund M., Struglics A., Lohmander L.S. Association between synovial fluid levels of aggrecan ARGS fragments and radiographic progression in knee osteoarthritis. Arthritis Res Ther 2010, 12:R230.
12. Larkin J. Linking an ADAMTS-5-specific therapeutic monoclonal antibody to a sensitive biochemical marker of target engagement and activity for potential application as a companion diagnostic. Osteoarthritis Cartilage 2012, 20:S290.
13. Bellamy N., Buchanan W.W., Goldsmith C.H., Campbell J., Stitt L.W. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. JRheumatol 1988, 15:1833-1840.
14. Deng H., O'Keefe H., Davie C.P., Lind K.E., Acharya R.A., Franklin G.J., et al. Discovery of highly potent and selective small molecule ADAMTS-5 inhibitors that inhibit human cartilage degradation via encoded library technology (ELT). JMed Chem 2012, 55:7061-7079.
15. Brittain I.J. Evaluation of an aggrecan biomarker for assessment of aggrecanase inhibitor activity. Osteoarthritis Cartilage 2009, 17(Suppl 1):S76-S77.
16. Deaver D.R. Anew non-isotopic detection system for immunoassays. Nature 1995, 377:758-760.
17. Bioanalytical Method Validation. FDA Guidance for Industry 2013 September, revision 1.
18. Jayadev C., Rout R., Price A., Hulley P., Mahoney D. Hyaluronidase treatment of synovial fluid to improve assay precision for biomarker research using multiplex immunoassay platforms. JImmunol Methods 2012, 386(1-2):22-30.
19. Duffield D.R., Nemirovskiy O.V., Jennings M.G., Tortorella M.D., Malfait A.M., Mathews W.R. An immunoaffinity liquid chromatography-tandem mass spectrometry assay for detection of endogenous aggrecan fragments in biological fluids: use as a biomarker for aggrecanase activity and cartilage degradation. Anal Biochem 2010, 406:113-123.
20. Hughes C.E., Caterson B., Fosang A.J., Roughley P.J., Mort J.S. Monoclonal antibodies that specifically recognize neoepitope sequences generated by 'aggrecanase' and matrix metalloproteinase cleavage of aggrecan: application to catabolism in situ and invitro. JBiochem 1995, 305:799-804.
21. Sward P., Frobell R., Englund M., Roos H., Struglics A. Cartilage and bone markers and inflammatory cytokines are increased in synovial fluid in the acute phase of knee injury (hemarthrosis) a cross-sectional analysis. Osteoarthritis Cartilage 2012, 20(11):1302-1308.
22. Anderson S.A., Loeser R.F. Why is osteoarthritis an age-related disease?. Best Pract Res Clin Rheumatol 2010; Feb, 24(1):15-26.